Mylan Confirms Availability of EpiPen® (epinephrine injection) Auto-Injector for U.S. Patients Affected by Sanofi's Auvi-Q® (epinephrine injection, USP) Recall

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. MU
8. NVDA
9. BLZE
10. NKE

Go back to Mylan Confirms Availability of EpiPen® (epinephrine injection) Auto-Injector for U.S. Patients Affected by Sanofi's Auvi-Q® (epinephrine injection, USP) Recall

RBC Capital Cuts Price Target on Mylan (MYL) Ahead of PRGO Acquisition Tender deadline

November 2, 2015 9:39 AM EST

RBC Capital maintained a Sector Perform rating on Mylan (NASDAQ: MYL), and cut the price target to $60.00 (from $64.00), as focus is now squarely on the 11/13 tender deadline in MYL's attempt to acquire PRGO. Lingering questions continue to surround the company.

Analyst Randall Stanicky... More

Mylan (MYL) Announces U.S. Court Denial of Perrigo's (PRFO) Preliminary Injunction Request

October 30, 2015 6:46 AM EDT

Mylan (NASDAQ: MYL) announced that the U.S. District Court for the Southern District of New York has denied the motion by Perrigo Company plc (NYSE: PRGO) for a preliminary injunction concerning Mylan's proposed acquisition of Perrigo, ruling that Mylan had provided adequate public disclosures regarding the synergies expected to be achieved from the combination.

The... More